Kewo Pharmaceutical announces the global first-in-human Phase I data of ES014 monotherapy in a verbal presentation at ESMO Asia.

On December 5, 2025, Kewoming Pharmaceuticals announced the results of the Phase I clinical trial of its independently developed dual-specific antibody ES014 at the European Society for Medical Oncology Asia Conference (ESMO Asia). ES014 is the world's first CD39/TGF dual-specific antibody independently developed by Kewoming Pharmaceuticals, and it is also the first to enter the clinical stage globally. It has shown preliminary and clinically significant anti-tumor activity in multiple cancer types with high unmet clinical needs. The research results show that in the treatment of desmoid tumors (DT), the objective response rate (ORR) of ES014 reaches 40% and the disease control rate (DCR) is 100%, providing a highly potential innovative treatment direction. In non-small cell lung cancer (NSCLC), ES014 shows preliminary efficacy in patients with high expression of CD39, laying the foundation for precise medication strategies for patients. It is also worth noting that ES014 may bring new treatment options for wild-type GIST patients with extremely limited choices in clinical treatment. With the initial benefits shown in clinical trials of core pipelines like ES014 and the establishment of the globally scarce Myeloid Cell Engager (MCE) platform, as a company deeply rooted in immunology and focused on innovative research, the certainty of value realization for Kewoming Pharmaceuticals will continue to increase. The potential for external authorization and cooperation in the international market will gradually become more evident. From the perspective of the long-term value of the innovative drug industry, once the clinical value of an innovative pipeline is internationally recognized, the sustainability of cash flow is expected to shift from "financing-driven" to "transaction and cooperation-driven".